Inhibrx Biosciences (INBX) EBT Margin (2023 - 2025)
Historic EBT Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Q2 2025 value amounting to 2204.0%.
- Inhibrx Biosciences' EBT Margin fell 18602170000.0% to 2204.0% in Q2 2025 from the same period last year, while for Sep 2025 it was 12031.34%, marking a year-over-year increase of 377265400.0%. This contributed to the annual value of 843787.0% for FY2024, which is 8571050000.0% up from last year.
- Inhibrx Biosciences' EBT Margin amounted to 2204.0% in Q2 2025, which was down 18602170000.0% from 1610.67% recorded in Q1 2025.
- Inhibrx Biosciences' EBT Margin's 5-year high stood at 1858013.0% during Q2 2024, with a 5-year trough of 156823.33% in Q2 2023.
- Over the past 3 years, Inhibrx Biosciences' median EBT Margin value was 3916.38% (recorded in 2023), while the average stood at 200569.03%.
- As far as peak fluctuations go, Inhibrx Biosciences' EBT Margin soared by 2000000000bps in 2024, and later plummeted by 2000000000bps in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' EBT Margin stood at 5628.76% in 2023, then plummeted by -750bps to 47865.0% in 2024, then surged by 95bps to 2204.0% in 2025.
- Its last three reported values are 2204.0% in Q2 2025, 1610.67% for Q1 2025, and 47865.0% during Q4 2024.